We translate Schedule I compound research from a regulatory tangle into a repeatable workflow. Our stack: a curated compound knowledge base, 29 expert agent personas grounded in real literature, and a DEA Schedule I application drafting toolkit that cuts counsel review from eight hours to two.
Built on CriOS Nova — Crowe Logic's quantum-enabled chemoinformatics engine — and a 194-agent system specialized for psychedelic tryptamines, phenethylamines, ergolines, and related scaffolds.
Curated records for 15 Schedule I and adjacent compounds, each with real PubMed-cited receptor Ki values, metabolic pathways, drug interactions, toxicology, and FDA status. Queryable by target receptor, potency threshold, or compound class.
$ lfpsy screen --target 5-HT2A --max-ki 50 LSD Ki=2.9 nM Psilocin Ki=4.6 nM Psilocybin Ki=6.0 nM Baeocystin Ki=18.5 nM …
24 Molecular Design specialists (Natural Product Chemist, AI-Driven Designer, Fluorine Specialist, Scaffold Hopping Expert…) plus 3 Psychedelic Specialist personas grounded in real PMIDs and CFR text, plus 2 Core orchestrators. Each agent ships as a reusable system prompt backed by curated citations.
$ lfpsy agents list --division \
psychedelic_specialist
psy_pharm_001 Dr. Evelyn Nakamura
psy_reg_001 Dr. Catherine Mullen
psy_clin_001 Dr. Jonathan Reyes
6 Psilocybe species and 6 commercial P. cubensis strains with peer-reviewed alkaloid profiles. Match a target profile (e.g. high-psilocybin, low-baeocystin) to ranked cultivar×strain candidates with predicted alkaloid content.
$ lfpsy cultivar-match \
--target-profile high-psilocybin,low-baeocystin
1. P. cubensis — Tidal Wave 100 ψ=2.00% ψn=1.47%
2. P. cubensis — Penis Envy 100 ψ=1.34%
3. P. cyanescens 96 ψ=1.31%
Three tiers. Each one buys down a specific class of regulatory or scientific friction.
$2,500/month
For: internal research teams at Schedule I registered institutions, psychedelic biotech startups in discovery phase.
$25,000/application
[LEGAL REVIEW] markers flag each ambiguity counsel must resolveFor: new registrants who need a submission-ready draft without paying counsel to boilerplate. Saves a typical 6-8 hour counsel review down to ~2.
$50,000/engagement
For: research facilities scaling psilocybin mushroom cultivation beyond bench scale.
Tier 2 (Q3 2026): CriOS Nova Psy API — on-demand receptor binding prediction, ADMET profiling, and novel analog generation. $5K/mo per seat. Tier 3 (2027): IND-support and DEA-registered compound characterization services.
Real pharmacology. Every receptor Ki traces to a PubMed citation.
| # | Name | Class | 5-HT2A Ki (nM) | Half-life | Schedule | FDA BT |
|---|---|---|---|---|---|---|
| CP-001 | Psilocybin | tryptamine | 6.0 | 2.5 h | I | ✓ |
| CP-002 | Psilocin | tryptamine | 4.6 | 2.5 h | I | |
| CP-003 | Baeocystin | tryptamine | 18.5 | — | I | |
| CP-006 | DMT | tryptamine | 127 | 0.25 h | I | |
| CP-007 | 5-MeO-DMT | tryptamine | 22 | 0.2 h | I | ✓ |
| CP-009 | Mescaline | phenethylamine | 5,500 | 6 h | I | |
| CP-010 | MDMA | entactogen | —* | 8 h | I | ✓ |
| CP-011 | Ibogaine | iboga alkaloid | —† | 7.5 h | I | |
| CP-012 | LSD | ergoline | 2.9 | 3.6 h | I | |
| CP-013 | Ketamine | arylcyclohexylamine | —‡ | 2.5 h | III | ✓ |
| CP-014 | Salvinorin A | neoclerodane | —§ | 0.08 h | — | |
| CP-015 | 2C-B | phenethylamine | 26 | 1.5 h | I |
* MDMA acts via SERT/NET/DAT, not 5-HT2A.
† Ibogaine acts via NMDA, kappa-opioid, sigma-2.
‡ Ketamine: NMDA antagonist.
§ Salvinorin A: selective kappa-opioid agonist (Ki 1.9 nM).
Full records for all 15 compounds in the CLI: lfpsy characterize --compound <name>.
Each agent is a curated system prompt with specializations, a decision procedure, and grounding citations. Each one can be invoked against Claude Opus via Azure AI Foundry (CroweLM Supreme).
Dr. Yuki Tanaka (Natural Products), Dr. Hiroshi Yamamoto (AI-Driven), Dr. Carlos Rodriguez (Fluorine), Dr. Nina Volkova (Deuterium), Dr. Michael Brown (Scaffold Hopping), Dr. Priya Sharma (Polypharmacology), Dr. Thomas Mueller (Prodrugs), and 17 others.
Dr. Evelyn Nakamura — medicinal chemistry, 5-HT2A bias, tryptamine SAR.
Dr. Catherine Mullen — DEA Schedule I regulatory, 21 CFR 1301, Federal Analog Act.
Dr. Jonathan Reyes — clinical psychopharmacology, MEQ-30/5D-ASC, MAPP1/MAPP2 Phase 3 design.
Mycelium Core — Crowe Logic methodology (OBSERVE→DECOMPOSE→CONNECT→SYNTHESIZE→VALIDATE), mycology grounding.
Dr. Ben Crowe Coder — pipeline automation and code generation across specialist divisions. The execution engine paired with Mycelium Core's decomposition.
Real artifacts generated by the platform. Not marketing fluff — download them, read them, show them to your counsel and your chemists.
Query: "Propose three novel 5-HT2A agonist tryptamines for TRD with specific selectivity profile." Response includes SMILES, crystal structure-guided rationale (PDB 6WHA/6WGT), predicted Ki with interpolation basis, ADMET concerns, and freedom-to-operate commentary. Grounded in PMIDs 27816818, 32699011, 28129538.
Query: "Walk a Phoenix-based in-vitro biotech through DEA Schedule I registration." Response covers researcher-vs-analytical-lab choice, applicable 21 CFR 1301 sections, realistic 8-16 week timeline, top three rejection risks with mitigations, IND-scope question, and state-level AZ factors. 10 CFR citations, 6 [LEGAL REVIEW] markers.
A full sample reg-pack generated from a single intake YAML: cover letter, research protocol summary, security plan (21 CFR 1301.71-76), three operational SOPs (inventory, destruction, emergency), facility diagram template, and DEA Form 225 field map. Every file watermarked "DRAFT — Legal review required."
Crowe Psychedelics is a division of Crowe Logic, Inc. For partnership, licensing, or platform-access inquiries: